Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics

por Dimopoulos, M. A., Kastritis, E., Ghobrial, I. M.
Publicado 2016

Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma

por Dimopoulos, M A, Hussein, M, Swern, A S, Weber, D
Publicado 2011

Immune checkpoint inhibitor administration during pregnancy: a case series

por Andrikopoulou, A., Korakiti, A.M., Apostolidou, K., Dimopoulos, M.A., Zagouri, F.
Publicado 2021

Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma

por Gkotzamanidou, M, Sfikakis, P P, Kyrtopoulos, S A, Bamia, C, Dimopoulos, M A, Souliotis, V L
Publicado 2014

Response to letter, ‘Immortal time bias in retrospective analysis'

por Dimopoulos, M A, Swern, A S, Li, J S, Hussein, M, Weiss, L, Nagarwala, Y, Baz, R
Publicado 2015

Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

por Dimopoulos, M A, Swern, A S, Li, J S, Hussein, M, Weiss, L, Nagarwala, Y, Baz, R
Publicado 2014

Correction: Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma

por Gkotzamanidou, M., Sfikakis, P. P., Kyrtopoulos, S. A., Bamia, C., Dimopoulos, M. A., Souliotis, V. L.
Publicado 2020

How we treat endocrine complications of immune checkpoint inhibitors

por Paschou, S.A., Stefanaki, K., Psaltopoulou, T., Liontos, M., Koutsoukos, K., Zagouri, F., Lambrinoudaki, I., Dimopoulos, M.-A.
Publicado 2021

Colon Adenoma Implicating Myasthenia Gravis: A Case Report of a Patient with Postcolectomy Complications

por Papachatzakis, Y., Tseliou, E., Tatouli, I., Dialoupi, I., Michas, F., Papadopoulou, E., Kousouris, D., Kontogiannis, S., Dimopoulos, M. A.
Publicado 2016

PB1983: TRIAL-IN-PROGRESS: PHASE II STUDY OF PHE885, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN ADULTS WITH RELAPSED AND/OR REFRACTORY MULTIP...

por Munshi, N., Spencer, A., Raab, M. S., Masood, A., Martinez-Prieto, M., Chu, J., Iida, S., Lonial, S., Dimopoulos, M. A.
Publicado 2022

Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging

por Kastritis, E, Gavriatopoulou, M, Dimopoulos, M A, Eleutherakis-Papaiakovou, E, Kanellias, N, Roussou, M, Pamboucas, C, Toumanidis, S T, Terpos, E
Publicado 2015

Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma

por Spanoudakis, E, Papoutselis, M, Terpos, E, Dimopoulos, M A, Tsatalas, C, Margaritis, D, Rahemtulla, A, Kotsianidis, I, Karadimitris, A
Publicado 2016

Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series

por Zagouri, F, Sergentanis, T N, Koutoulidis, V, Sparber, C, Steger, G G, Dubsky, P, Zografos, G C, Psaltopoulou, T, Gnant, M, Dimopoulos, M-A, Bartsch, R
Publicado 2013

Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy

por Liontos, M., Andrikopoulou, A., Koutsoukos, K., Markellos, C., Skafida, E., Fiste, O., Kaparelou, M., Thomakos, N., Haidopoulos, D., Rodolakis, A., Dimopoulos, M. A., Zagouri, F.
Publicado 2021

P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

por Kastritis, E., Minnema, M. C., Dimopoulos, M. A., Merlini, G., Theodorakakou, F., Fotiou, D., Huart, A., Belhadj, K., Gkolfinopoulos, S., Manousou, K., Sonneveld, P., Palladini, G.
Publicado 2022

Axitinib as a third or further line of treatment in renal cancer: a single institution experience

por Tsironis, G., Liontos, M., Kyriazoglou, A., Koutsoukos, K., Tsiara, A., Kaparelou, M., Zakopoulou, R., Cohen, A., Skafida, E., Fontara, S., Zagouri, F., Bamias, A., Dimopoulos, M. A.
Publicado 2020

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

por Kastritis, E., Palladini, G., Dimopoulos, M. A., Jaccard, A., Merlini, G., Theodorakakou, F., Fotiou, D., Minnema, M. C., Wechalekar, A., Gkolfinopoulos, S., Manousou, K., Sonneveld, P., Schönland, S.
Publicado 2022

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

por Zagouri, F, Bago-Horvath, Z, Rössler, F, Brandstetter, A, Bartsch, R, Papadimitriou, C A, Dimitrakakis, C, Tsigginou, A, Papaspyrou, I, Giannos, A, Dimopoulos, M-A, Filipits, M
Publicado 2013

Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment

por Terpos, E, Migkou, M, Christoulas, D, Gavriatopoulou, M, Eleutherakis-Papaiakovou, E, Kanellias, N, Iakovaki, M, Panagiotidis, I, Ziogas, D C, Fotiou, D, Kastritis, E, Dimopoulos, M A
Publicado 2016

B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA

por Terpos, E, Gavriatopoulou, M, Ntanasis-Stathopoulos, I, Briasoulis, A, Gumeni, S, Malandrakis, P, Papanagnou, E-D, Migkou, M, Kanellias, N, Kastritis, E, Trougakos, I P, Dimopoulos, M A
Publicado 2022